Drugs News and Research

RSS

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

Bay Area health care start-up investments down 35% in third quarter

In California's Bay Area, third-quarter venture capital investment in health care-related companies totaled $421.5 million, down 35 percent from $650.6 million in the same period a year earlier, according to research firm VentureSource.

11 Nov 2010

Women and cancer today

Experts have warned that women who have their breasts removed out of fear of a high hereditary risk of breast cancer may be doing so needlessly. Genetic tests like for the BRCA mutations have predicted a high risk of getting breast cancer in women with many breast cancer sufferers among their first degree relatives. Earlier studies suggest the risk of the mutation to predict the cancer 87% of the time. Now experts want that this is an overestimate.

11 Nov 2010

Think treatments for cancer, diabetes don't grow on trees? Think again

Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.

11 Nov 2010

Healthcare cost climbs for people with employer-sponsored health insurance: Thomson Reuters index

The cost of healthcare for people with employer-sponsored health insurance climbed an estimated 6.3 percent for the year ending June 30, according to a new Thomson Reuters index.

11 Nov 2010

World's largest data base on protein motions

After four years of conducting intensive calculations in the supercomputer MareNostrum at the Barcelona Supercomputing Center, scientists headed by Modesto Orozco at the Institute for Research in Biomedicine (IRB Barcelona) have presented the world's largest data base on protein motions. Called MoDEL, this new database holds more than 1,700 proteins and is partially accessible through Internet to researchers worldwide. MoDEL has been developed to study the basic biology of proteins and to accelerate and facilitate the design of new pharmaceutical agents.

11 Nov 2010

Neuron subtypes control level of fear output from amygdala

The eerie music in the movie theater swells; the roller coaster crests and begins its descent; something goes bump in the night. Suddenly, you're scared: your heart thumps, your stomach clenches, your throat tightens, your muscles freeze you in place. But fear doesn't come from your heart, your stomach, your throat, or your muscles. Fear begins in your brain, and it is there specifically in an almond shaped structure called the amygdala that it is controlled, processed, and let out of the gate to kick off the rest of the fear response.

11 Nov 2010

Most drug and biological product makers meet postmarketing requirements and commitments

Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).

11 Nov 2010

New findings suggest serotonin may have anti-diabetic property

New findings by researchers at UT Southwestern Medical Center suggest that serotonin a brain chemical known to help regulate emotion, mood and sleep might also have anti-diabetic properties.

11 Nov 2010

Cancer Research UK presents inaugural prizes at National Conference in Liverpool

The first ever Cancer Research UK prizes were presented this week at the National Cancer Research Institute Cancer Conference in Liverpool.

11 Nov 2010

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Scientists are reporting development of a long-sought method with the potential for getting medication through a biological barrier that surrounds the brain, where it may limit the brain damage caused by stroke. Their approach for sneaking the nerve-protective drug erythropoietin into the brain is medicine's version of the Trojan Horse ploy straight out of ancient Greek legend.

11 Nov 2010

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

In a major breakthrough that comes after decades of research and nearly half a billion treatments in humans, scientists have finally unlocked how a key anti-parasitic drug kills the worms brought on by the filarial diseases river blindness and elephantitis.

11 Nov 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

New research has found that a mother's poor nutrition during pregnancy and nursing can cause problems for her offspring's ability to process medications, even well into adulthood.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

New discovery can develop diagnostic test to identify gene mutation in AML

Decoding the DNA of a woman who died of acute myeloid leukemia (AML) has led researchers at Washington University School of Medicine in St. Louis to a gene that they found to be commonly altered in many patients who died quickly of the disease.

11 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010

Lemon-lime soft drink could improve effectiveness of oral anticancer drug: Study

Experiments with an artificial stomach suggest that a popular lemon-lime soft drink could play an unexpected role in improving the effectiveness of an oral anticancer drug. The experiments produced evidence that patients will absorb more of the unnamed drug, tested in Phase I in clinical trials, when taken with "flat" or degassed Sprite. The study appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

11 Nov 2010

Drugs News and Research

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Bay Area health care start-up investments down 35% in third quarter

Women and cancer today

Think treatments for cancer, diabetes don't grow on trees? Think again

Healthcare cost climbs for people with employer-sponsored health insurance: Thomson Reuters index

World's largest data base on protein motions

Neuron subtypes control level of fear output from amygdala

Most drug and biological product makers meet postmarketing requirements and commitments

New findings suggest serotonin may have anti-diabetic property

Cancer Research UK presents inaugural prizes at National Conference in Liverpool

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

Researchers identify molecular cascade that drives sprouting in brain after stroke

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

New discovery can develop diagnostic test to identify gene mutation in AML

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

Lemon-lime soft drink could improve effectiveness of oral anticancer drug: Study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News